
Psyence Biomedical fell 84.4% from $18.13 to $2.83, behind the S&P 500's +11.2%. Its worst day was Nov 20 (−38.4%), and its low came Feb 23 at $2.23.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Psyence Biomedical shares fell 38.4%, while the S&P 500 fell 1.5%.
−38.4%, the year's worst day · S&P 500 −1.5%
Story events cover the past 12 months · Times ET
Psyence Biomedical shares fell 31.5%, while the S&P 500 rose 0.9%.
−31.5% · S&P 500 +0.9%
Psyence Biomedical shares rose 30.0%, while the S&P 500 rose 1.2%.
+30.0% · S&P 500 +1.2%
Psyence Biomedical closed at its lowest level of the year, 87.7% below where the year started.
−10.8% · S&P 500 −1.0%
Psyence Biomedical shares rose 103.8%, while the S&P 500 rose 0.2%.
+103.8%, the year's best day, on 54M shares, the year's heaviest volume · S&P 500 +0.2%
Psyence Biomedical shares rose 29.7%, while the S&P 500 rose 1.0%.
+29.7% · S&P 500 +1.0%
EPS of $-12.56 was reported on $0.00 revenue.
−6.1% · S&P 500 −1.5%
Where it ended: a close of $2.83 on Nov 16, 2026. Up next: Q3 2025 earnings on Dec 1, 2026.
Nothing in the past 12 months.
All PBM analyst actionsNothing in the past 12 months.
All PBM dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PBM and SPY from Benzinga historical bars. Not investment advice.